Brazilian production was possible after the fall of patents last year of the Danish medicines Victoza e Saxendawhich are based on the same active ingredient.
The purpose of EMS was that national products were marketed at prices 10% to 20% lower than reference medicines. According to the EstadãoHowever, the Danish pens were being sold last Friday (1/8), with discounts of more than 30% on drugs sites.
Olire and Larux are available from this Monday, in physical stores of Raia, Drogasil, Drugstore Sao Paulo and Pacheco Drugstores in the South and Southeast regions of the country, according to the manufacturer. To other locations, medicines should arrive over the coming weeks, and by the end of this year, 250,000 units of them should be available for purchase in the national territory.
How it works
Liraglutide, an active ingredient of the injectable pens olire and lurux, limits the action of the hormone LPG-1, which acts on areas of the brain responsible for hunger control and slows the stomach emptying. Thus, it helps to control the appetite by causing the user to feel satiated, and reduces his desire to eat, which generates weight loss. Lirux also controls blood sugar levels, both in fasting and after meals.
Unlike other principles that simulate GLP-1, such as semaglutide-of Ozepic and WeGovy medicines-and tirzepatida-from Mounjaro-, which are for weekly use, the lyglutide should be used daily.
After investing more than R $ 1 billion to enable the production of weight loss drugs in Brazil – including the inauguration of the first peptide factory in the country, which has the capacity to produce 20 million pens per year – EMS prepares to launch semaglutidal medicines as soon as the patent of reference brands fall in 2026.
The use of injecting medicines should be done under medical prescription, associated with hypocaloric diet and regular practice of physical activity. According to the laboratory, Olire is suitable for adults and adolescents from 12 years in obesity or overweight – that is, with body mass index (BMI) greater than 27 -; Lirux ensures effective control of type 2 diabetes in adults, adolescents and children from 10 years.
